Adenovirus-derived vectors for prostate cancer gene therapy.
Prostate cancer is a leading cause of death among men in Western countries. Whereas the survival rate approaches 100% for patients with localized cancer, the results of treatment in patients with metastasized prostate cancer at diagnosis are much less successful. The patients are usually presented with a variety of treatment options, but therapeutic interventions in prostate cancer are associated with frequent adverse side effects. Gene therapy and oncolytic virus therapy may constitute new strategies. Already a wide variety of preclinical studies has demonstrated the therapeutic potential of such approaches, with oncolytic prostate-specific adenoviruses as the most prominent vector. The state of the art and future prospects of gene therapy in prostate cancer are reviewed, with a focus on adenoviral vectors. We summarize advances in adenovirus technology for prostate cancer treatment and highlight areas where further developments are necessary.
de Vrij
Jeroen
J
Department of Molecular Cell Biology, Leiden University Medical Center , 2300 RC Leiden, The Netherlands.
Willemsen
Ralph A
RA
Lindholm
Leif
L
Hoeben
Rob C
RC
Bangma
Chris H
CH
Barber
Chris
C
Behr
Jean-Paul
JP
Briggs
Simon
S
Carlisle
Robert
R
Cheng
Wing-Shing
WS
Dautzenberg
Iris J C
IJ
de Ridder
Corrina
C
Dzojic
Helena
H
Erbacher
Patrick
P
Essand
Magnus
M
Fisher
Kerry
K
Frazier
April
A
Georgopoulos
Lindsay J
LJ
Jennings
Ian
I
Kochanek
Stefan
S
Koppers-Lalic
Daniela
D
Kraaij
Robert
R
Kreppel
Florian
F
Magnusson
Maria
M
Maitland
Norman
N
Neuberg
Patrick
P
Nugent
Regina
R
Ogris
Manfred
M
Remy
Jean-Serge
JS
Scaife
Michelle
M
Schenk-Braat
Ellen
E
Schooten
Erik
E
Seymour
Len
L
Slade
Michael
M
Szyjanowicz
Pio
P
Totterman
Thomas
T
Uil
Taco G
TG
Ulbrich
Karel
K
van der Weel
Laura
L
van Weerden
Wytske
W
Wagner
Ernst
E
Zuber
Guy
G
D000256:Adenoviridae / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods / Q000639:trends; D005822:Genetic Vectors / Q000235:genetics*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy*